AN ECONOMIC EVALUATION OF GENERIC DRUG ENTRIES IN TURKISH PHARMACEUTICAL MARKET

Author(s)

Bektemur G1, Safak Yilmaz E2, Atikeler EK3, Vural IM2, Nacar S2, Beyan A2, Bayar B2, Gursoz H2
1Health Sciences University, Ankara, Turkey, 2Turkish Medicines and Medical Devices Agency, Ankara, Turkey, 3Turkish Medicines and Medical Devices Agency, Ankara, 06, Turkey

OBJECTIVES: The objective of the study is to understand the effects of generic entry on the price of the original drug, to present these results to us and show the generic competition occur on the conditions of increased generic drug number situation.

METHODS: RESULTS: This paper concerns the impact of generic competition on the market unit price ratio of original drugs and our study has shown that the effects of generic drug entrance to market on original drug unit price are significant and enduring. But this effect ends up with more than 6 generic entries. While the data in this study is restricted to last 10 years, it is likely that being first generic into the market, has more effects on original drug market share.

CONCLUSIONS: Government policies for pharmaceutical market that allow early entry to market for generics together with or without financial incentives for use of generics can achieve both increasing generic consumption and price competition. Tenders and INN prescription system increase generic uptake and allow price competition between originator and generics.

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PHP344

Topic

Health Policy & Regulatory

Topic Subcategory

Approval & Labeling

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×